But for Rock, one thing was clear: "They do work." "For years and years and years I lived in a world where it was always 'someday,' 'I'll do it when,' but now that's today," she said
At a glance Status : Confirmed GLP-1 receptor agonist use (specific drug not publicly disclosed) Medical context : Pre-existing autoimmune thyroid condition requiring medication Timeline : Public confirmation in 2024 interviews Discontinuation status : Not publicly confirmed whether she has stopped or continues treatment Clinical focus of this page : What peer-reviewed evidence says about GLP-1 discontinuation, regain risk, and maintenance in patients with thyroid comorbidities The Discontinuation Problem: What the Trials Show The single most replicated finding in GLP-1 obesity research is that stopping the medication leads to weight regain
Adil Farooq Wali, [email protected]
pylori eradication, expanding GI treatment scope CG MedTech completes smart office, expands implant production capacity Daewoong, FMI invest in General Proximity to advance induced-proximity drugs Dong-A University Hospital rolls out regions largest AI smart ward with Daewoong Daewoong, Puzzle AI partner to launch AI medical record platform CL Note Daewoongs Fexuclue wins Indonesia nod, expands into Southeast Asia P-CAB market MetaVias obesity drug candidate DA-1726 to be presented at European liver meeting Daewoong takes over US anti-aging platform in $239 mil-linked deal Beyond weight loss: Korean drugmakers to showcase obesity innovation at ADA 2026 Kim Ji-hye [email protected]
